Adam10tm1.1Dhc/Adam10tm1.1Dhc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL
|
abnormal B cell differentiation |
J:158127
|
|
absent marginal zone B cells |
J:158127
|
|
decreased transitional stage T2 B cell number |
J:158127
|
|
increased follicular B cell number |
J:158127
|
|
increased transitional stage T1 B cell number |
J:158127
|
Bak1tm1Thsn/Bak1tm1Thsn
Baxtm1Sjk/Baxtm2Sjk
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
abnormal B cell number |
J:100463
|
|
abnormal B cell physiology |
J:100463
|
|
decreased marginal zone B cell number |
J:100463
|
|
increased B cell number |
J:100463
|
|
increased B-2 B cell number |
J:100463
|
|
increased bone marrow cell number |
J:100463
|
|
increased follicular B cell number |
J:100463
|
|
increased IgA level |
J:100463
|
|
increased IgG level |
J:100463
|
|
increased IgM level |
J:100463
|
|
increased immunoglobulin level |
J:100463
|
|
increased pre-B cell number |
J:100463
|
|
increased pro-B cell number |
J:100463
|
|
increased transitional stage B cell number |
J:100463
|
Bcl10tm1Mak/Bcl10tm1Mak
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd
|
normal
immune system phenotype |
J:228288
|
|
normal
mortality/aging |
J:228288
|
Birc2tm1Rbr/Birc2tm1Rbr
Birc3tm1.1Rbr/Birc3tm1.1Rbr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * NZB
|
decreased B cell apoptosis |
J:172843
|
|
decreased germinal center B cell number |
J:172843
|
|
decreased spleen germinal center size |
J:172843
|
|
enlarged lymph nodes |
J:172843
|
|
enlarged spleen |
J:172843
|
|
increased B cell number |
J:172843
|
|
increased follicular B cell number |
J:172843
|
|
increased marginal zone B cell number |
J:172843
|
Birc2tm1Rbr/Birc2tm1Rbr
Birc3tm1.1Rbr/Birc3tm1.1Rbr
Cd19tm1(cre)Cgn/Cd19+
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6 * NZB
|
normal
immune system phenotype |
J:172843
|
Birc2tm1Rbr/Birc2tm1Rbr
Birc3tm1Rbr/Birc3tm1Rbr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * NZB
|
normal
immune system phenotype |
J:172843
|
Blmtm4Ches/Blmtm4Ches
Cd19tm1(cre)Cgn/Cd19+
Nsmce2tm2.1Ofc/Nsmce2tm2.1Ofc
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal B cell morphology |
J:227197
|
|
abnormal B cell physiology |
J:227197
|
|
decreased B cell number |
J:227197
|
|
elevated level of mitotic sister chromatid exchange |
J:227197
|
|
small spleen |
J:227197
|
Blmtm4Ches/Blmtm4Ches
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
abnormal class switch recombination |
J:194603
|
Blnktm1Dkit/Blnktm1Dkit
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
involves: 129P2/OlaHsd * C57BL/6 * NZB
|
abnormal pre-B cell morphology |
J:84040
|
|
absent immature B cells |
J:84040
|
|
absent mature B cells |
J:84040
|
|
arrested B cell differentiation |
J:84040
|
|
decreased pre-B cell number |
J:84040
|
|
enlarged lymph nodes |
J:84040
|
|
enlarged spleen |
J:84040
|
|
increased leukemia incidence |
J:84040
|
Bod1lem1Bltn/Bod1lem1Bltn
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6J
|
decreased IgG1 level |
J:337726
|
|
decreased IgG level |
J:337726
|
Brca1tm2Cxd/Brca1tm2Cxd
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
chromosome breakage |
J:197442
|
Brca1tm2Cxd/Brca1tm2Cxd
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
normal
cellular phenotype |
J:197442
|
Brca2tm1Brn/Brca2tm1Brn
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd
|
chromosome breakage |
J:197442
|
Brca2tm1Brn/Brca2tm1Brn
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd
|
chromosome breakage |
J:197442
|
Casp8tm1Hed/Casp8tm1Hed
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd
|
abnormal adaptive immunity |
J:116713
|
|
abnormal immunoglobulin level |
J:116713
|
|
decreased B cell number |
J:116713
|
|
decreased B cell proliferation |
J:116713
|
|
decreased B-1 B cell number |
J:116713
|
|
decreased marginal zone B cell number |
J:116713
|
|
increased apoptosis |
J:116713
|
|
spleen hypoplasia |
J:116713
|
Cd19tm1(cre)Cgn/Cd19+
Faslpr/Fastm1Cgn
involves: 129P2/OlaHsd * C57BL/6 * MRL
|
enlarged lymph nodes |
J:114948
|
|
enlarged spleen |
J:114948
|
Cd19tm1(cre)Cgn/Cd19+
Faslpr/Fastm1Cgn
Tg(Cd4-cre)1Cwi/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL
|
enlarged lymph nodes |
J:114948
|
|
enlarged spleen |
J:114948
|
|
increased double-negative T cell number |
J:114948
|
Cd19tm1(cre)Cgn/Cd19+
Pax5tm1Mbu/Pax5tm3Mbu
involves: 129P2/OlaHsd * 129S2/SvPas
|
abnormal B cell differentiation |
J:75504
|
|
abnormal class switch recombination |
J:75504
|
|
decreased IgG1 level |
J:75504
|
|
decreased IgG3 level |
J:75504
|
|
decreased IgG level |
J:75504
|
|
decreased immature B cell number |
J:75504
|
|
decreased immunoglobulin level |
J:75504
|
|
decreased mature B cell number |
J:75504
|
|
decreased pre-B cell number |
J:75504
|
Cd19tm1(cre)Cgn/Cd19+
Cxcr4tm1Tng/Cxcr4tm2Tng
involves: 129P2/OlaHsd * C57BL/6
|
decreased plasma cell number |
J:109147
|
Cd19tm1(cre)Cgn/Cd19+
Gna11tm1Soff/Gna11tm1Soff
Gnaqtm2Soff/Gnaqtm2Soff
B6N.129-Cd19tm1(cre)Cgn Gna11tm1Soff Gnaqtm2Soff
|
normal
hematopoietic system phenotype |
J:117663
|
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae
|
abnormal B cell negative selection |
J:155314
|
|
abnormal B cell physiology |
J:83213
|
|
abnormal class switch recombination |
J:114881
|
|
abnormal plasma cell morphology |
J:114881
|
|
decreased IgG level |
J:114881
|
|
decreased spleen germinal center number |
J:83213
|
|
increased B cell apoptosis |
J:83213
|
|
increased B cell number |
J:83213
|
|
increased B cell proliferation |
J:83213,
J:155314
|
|
increased B-1 B cell number |
J:83213
|
|
increased IgM level |
J:114881
|
|
increased marginal zone B cell number |
J:83213
|
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal peripheral B cell anergy |
J:155314
|
Cd19tm1(cre)Cgn/Cd19+
Gna12tm1Citb/Gna12tm1Citb
Gna13tm2.1Soff/Gna13tm2.1Soff
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6N
|
abnormal B cell physiology |
J:117663
|
|
decreased marginal zone B cell number |
J:117663
|
Cd19tm1(cre)Cgn/Cd19+
Tnfsf13btm1Msc/Tnfsf13btm1Msc
Traf2tm1Rbr/Traf2tm1Rbr
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
increased follicular B cell number |
J:132877
|
|
increased marginal zone B cell number |
J:132877
|
Cd19tm1(cre)Cgn/Cd19+
Ltbtm1Avt/Ltbtm1Avt
involves: 129P2/OlaHsd * C57BL/6
|
abnormal adaptive immunity |
J:79129
|
|
abnormal spleen B cell follicle morphology |
J:79129
|
|
abnormal spleen follicular dendritic cell network |
J:79129
|
|
decreased marginal zone B cell number |
J:79129
|
|
decreased spleen germinal center number |
J:79129
|
|
decreased spleen germinal center size |
J:79129
|
|
small Peyer's patches |
J:79129
|
Cd19tm1(cre)Cgn/Cd19+
Ltbtm1Avt/Ltbtm1Avt
Tg(Lck-cre)1Jtak/?
involves: 129P2/OlaHsd * C57BL/6
|
absent follicular dendritic cells |
J:79129
|
Cd19tm1(cre)Cgn/Cd19+
Ikbkbtm2Mka/Ikbkbtm2Mka
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
abnormal B cell activation |
J:82995
|
|
decreased B cell number |
J:82995
|
|
decreased B cell proliferation |
J:82995
|
|
decreased B-1 B cell number |
J:82995
|
|
decreased IgG level |
J:82995
|
|
decreased IgM level |
J:82995
|
|
decreased marginal zone B cell number |
J:82995
|
|
increased B cell apoptosis |
J:82995
|
Cd19tm1(cre)Cgn/Cd19+
Ikbkbtm2Cgn/Ikbkbtm2.1Cgn
involves: 129P2/OlaHsd * C57BL/6
|
decreased B-1 B cell number |
J:79132
|
|
decreased follicular B cell number |
J:79132
|
|
decreased marginal zone B cell number |
J:79132
|
|
decreased mature B cell number |
J:79132
|
Cd19tm1(cre)Cgn/Cd19+
Ifnar1tm1Uka/Ifnar1tm1Uka
B6.129P2-Cd19tm1(cre)Cgn Ifnar1tm1Uka
|
decreased IgG1 level |
J:129128
|
|
decreased IgG2a level |
J:129128
|
|
decreased IgG3 level |
J:129128
|
|
decreased IgM level |
J:129128
|
Cd19tm1(cre)Cgn/Cd19+
Igbp1tm1Imku/Y
involves: 129P2/OlaHsd
|
abnormal B cell physiology |
J:74619
|
|
abnormal somatic hypermutation frequency |
J:74619
|
|
abnormal spleen germinal center morphology |
J:74619
|
|
decreased B cell number |
J:74619
|
|
decreased B cell proliferation |
J:74619
|
|
decreased follicular B cell number |
J:74619
|
|
decreased immunoglobulin level |
J:74619
|
|
decreased pre-B cell number |
J:74619
|
Cd19tm1(cre)Cgn/Cd19+
Notch2tm1.1Hhi/Notch2+
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
decreased marginal zone B cell number |
J:83476
|
Cd19tm1(cre)Cgn/Cd19+
Notch2tm2Hhi/Notch2tm1.1Hhi
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
abnormal spleen marginal zone morphology |
J:83476
|
|
absent marginal zone B cells |
J:83476
|
|
decreased transitional stage B cell number |
J:83476
|
Cd19tm1(cre)Cgn/Cd19+
Srsf3tm1Pjln/Srsf3tm1Pjln
involves: 129P2/OlaHsd * BALB/c
|
decreased B cell number |
J:113645
|
Cd19tm1(cre)Cgn/Cd19+
Ikbkbtm1Cgn/Ikbkbtm1.1Cgn
involves: 129P2/OlaHsd * C57BL/6
|
decreased B-1 B cell number |
J:79132
|
|
decreased follicular B cell number |
J:79132
|
|
decreased immature B cell number |
J:79132
|
|
decreased marginal zone B cell number |
J:79132
|
|
decreased mature B cell number |
J:79132
|
|
increased B cell proliferation |
J:79132
|
Cd19tm1(cre)Cgn/Cd19+
Ikbkgtm1.1Mpa/Y
involves: 129P2/OlaHsd * C57BL/6
|
decreased B-1 B cell number |
J:79132
|
|
decreased follicular B cell number |
J:79132
|
|
decreased immature B cell number |
J:79132
|
|
decreased marginal zone B cell number |
J:79132
|
|
decreased mature B cell number |
J:79132
|
|
increased B cell proliferation |
J:79132
|
Cd19tm1(cre)Cgn/Cd19+
Mcl1tm2Sjk/Mcl1tm3Sjk
involves: 129P2/OlaHsd * 129X1/SvJ
|
abnormal B cell differentiation |
J:86906
|
|
absent early pro-B cells |
J:86906
|
|
absent late pro-B cells |
J:86906
|
|
absent pre-B cells |
J:86906
|
|
arrested B cell differentiation |
J:86906
|
|
decreased B cell number |
J:86906
|
|
increased B cell apoptosis |
J:86906
|
Cd19tm1(cre)Cgn/Cd19+
Rac1tm1Tyb/Rac1tm1Tyb
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
normal
immune system phenotype |
J:86765
|
Cd19tm1(cre)Cgn/Cd19+
Rac1tm1Tyb/Rac1tm1Tyb
Rac2tm1Mddw/Rac2tm1Mddw
involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6
|
arrested B cell differentiation |
J:86765
|
|
decreased B cell number |
J:86765
|
|
decreased B-1 B cell number |
J:86765
|
|
decreased follicular B cell number |
J:86765
|
|
decreased marginal zone B cell number |
J:86765
|
|
decreased transitional stage B cell number |
J:86765
|
Cd19tm1(cre)Cgn/Cd19+
Tgfbr2tm1Roes/Tgfbr2tm1Roes
involves: 129P2/OlaHsd * BALB/c
|
abnormal B cell physiology |
J:90558
|
|
abnormal B-1 B cell morphology |
J:90558
|
|
abnormal B-1 B cell number |
J:90558
|
|
absent plasma cells |
J:90558
|
|
decreased IgA level |
J:90558
|
|
enlarged Peyer's patches |
J:90558
|
|
increased IgG level |
J:90558
|
|
increased IgM level |
J:90558
|
|
increased leukocyte cell number |
J:90558
|
Cd19tm1(cre)Cgn/Cd19+
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell differentiation |
J:172843
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(DTA)Riet/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd
|
decreased B cell number |
J:92789
|
Cd19tm1(cre)Cgn/Cd19+
Traf2tm1Rbr/Traf2tm1Rbr
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:132877
|
|
increased follicular B cell number |
J:132877
|
|
increased marginal zone B cell number |
J:132877
|
|
lymph node hyperplasia |
J:132877
|
Cd19tm1(cre)Cgn/Cd19+
Traf2tm1Rbr/Traf2tm1Rbr
Traf3tm1Rbr/Traf3tm1Rbr
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal B cell physiology |
J:132877
|
|
increased marginal zone B cell number |
J:132877
|
Cd19tm1(cre)Cgn/Cd19+
Il10tm1Roer/Il10tm1Roer
involves: 129P2/OlaHsd
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:151551
|
|
abnormal myeloid leukocyte morphology |
J:151551
|
|
decreased circulating interleukin-10 level |
J:151551
|
|
increased B cell number |
J:151551
|
|
increased CD4-positive, alpha-beta T cell number |
J:151551
|
|
increased plasma cell number |
J:151551
|
Cd19tm1(cre)Cgn/Cd19+
Rbpjtm1Hon/Rbpjtm1Hon
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell differentiation |
J:76240
|
|
decreased marginal zone B cell number |
J:76240,
J:121523
|
|
increased follicular B cell number |
J:76240,
J:121523
|
|
increased IgG3 level |
J:76240
|
|
increased susceptibility to bacterial infection |
J:76240
|
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:76240
|
Cd19tm1(cre)Cgn/Cd19+
Rbpjtm1Hon/Rbpjtm1Hon
Spentm2.1Hon/Spentm2.1Hon
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
decreased marginal zone B cell number |
J:121523
|
|
increased follicular B cell number |
J:121523
|
Cd19tm1(cre)Cgn/Cd19+
Fastm1Ach/Fastm1Ach
involves: 129P2/OlaHsd * BALB/c
|
enlarged spleen |
J:123556
|
|
increased anti-nuclear antigen antibody level |
J:123556
|
|
increased immunoglobulin level |
J:123556
|
|
increased lymphocyte cell number |
J:123556
|
Cd19tm1(cre)Cgn/Cd19+
Klhl6tm2Sato/Klhl6tm2Sato
either: (involves: 129P2/OlaHsd * 129T2/SvEms) or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * CD-1)
|
abnormal B cell differentiation |
J:101363
|
|
abnormal lymph node germinal center morphology |
J:101363
|
|
decreased B cell number |
J:101363
|
Cd19tm1(cre)Cgn/Cd19+
Prdm1tm1Clme/Prdm1tm1Clme
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
|
abnormal B cell differentiation |
J:101890
|
|
abnormal memory B cell number |
J:101890
|
|
abnormal plasma cell differentiation |
J:101890
|
|
abnormal plasma cell morphology |
J:101890,
J:114881
|
|
decreased IgG level |
J:101890
|
|
decreased IgM level |
J:101890
|
|
decreased immunoglobulin level |
J:101890
|
|
decreased plasma cell number |
J:101890
|
|
increased spleen germinal center number |
J:101890
|
|
increased spleen germinal center size |
J:101890
|
Cd19tm1(cre)Cgn/Cd19+
Tnftm2.1Gkl/Tnftm2.1Gkl
involves: 129P2/OlaHsd * 129S/SvEv * 129S6/SvEvTac * C57BL/6J
|
normal
immune system phenotype |
J:108572
|
Cd19tm1(cre)Cgn/Cd19+
Ube2ntm1Aki/Ube2ntm1Aki
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:112287
|
|
abnormal humoral immune response |
J:112287
|
|
abnormal spleen marginal zone morphology |
J:112287
|
|
decreased B cell number |
J:112287
|
|
decreased B cell proliferation |
J:112287
|
|
decreased immunoglobulin level |
J:112287
|
|
decreased marginal zone B cell number |
J:112287
|
|
increased B cell apoptosis |
J:112287
|
Cd19tm1(cre)Cgn/Cd19+
Map3k7tm1Aki/Map3k7tm1.1Aki
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:112597
|
|
decreased B cell proliferation |
J:112597
|
|
decreased B-1 B cell number |
J:112597
|
|
decreased IgG1 level |
J:112597
|
|
decreased IgG3 level |
J:112597
|
|
decreased IgG level |
J:112597
|
|
decreased immunoglobulin level |
J:112597
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(CTNNB1)Nerl/Gt(ROSA)26Sortm1(CTNNB1)Nerl
involves: 129P2/OlaHsd * BALB/c
|
normal
immune system phenotype |
J:112660
|
Cd19tm1(cre)Cgn/Cd19+
Pdia3tm1Gjh/Pdia3tm1Gjh
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:112606
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:113365
|
|
abnormal splenic cell ratio |
J:113365
|
|
decreased B cell apoptosis |
J:113365
|
|
increased B cell number |
J:113365
|
|
increased cell proliferation |
J:113365
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6
|
normal
immune system phenotype |
J:113365
|
Cd19tm1(cre)Cgn/Cd19+
Spi1tm2Dgt/Spi1tm2Dgt
involves: 129P2/OlaHsd * C57BL/6
|
normal
hematopoietic system phenotype |
J:114150
|
Cd19tm1(cre)Cgn/Cd19+
Fastm1Cgn/Fastm1Cgn
B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn
|
increased anti-single stranded DNA antibody level |
J:114948
|
Cd19tm1(cre)Cgn/Cd19+
Spentm2.1Hon/Spentm2.1Hon
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
decreased follicular B cell number |
J:121523
|
|
increased marginal zone B cell number |
J:121523
|
Cd19tm1(cre)Cgn/Cd19+
Inpp5dtm1Rav/Inpp5dtm1Rav
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae
|
abnormal B cell morphology |
J:166155
|
|
abnormal B cell physiology |
J:166155
|
|
abnormal coat appearance |
J:166155
|
|
abnormal myeloid leukocyte morphology |
J:166155
|
|
decreased B cell number |
J:166155
|
|
enlarged spleen |
J:166155
|
|
hunched posture |
J:166155
|
|
increased B cell number |
J:166155
|
|
increased B cell proliferation |
J:166155
|
|
increased follicular lymphoma incidence |
J:166155
|
|
increased lymphoma incidence |
J:166155
|
|
increased malignant tumor incidence |
J:166155
|
|
increased plasmacytoma incidence |
J:166155
|
|
increased spleen white pulp amount |
J:166155
|
|
increased splenic marginal zone lymphoma incidence |
J:166155
|
|
lethargy |
J:166155
|
|
premature death |
J:166155
|
|
weight loss |
J:166155
|
Cd19tm1(cre)Cgn/Cd19+
Ptpn6tm1Rsky/Ptpn6tm1Rsky
involves: 129P2/OlaHsd * C57BL/6
|
abnormal humoral immune response |
J:123568
|
|
abnormal immune system physiology |
J:123568
|
|
abnormal leukocyte cell number |
J:123568
|
|
abnormal lymph organ size |
J:123568
|
|
decreased B cell proliferation |
J:123568
|
|
decreased follicular B cell number |
J:123568
|
|
decreased marginal zone B cell number |
J:123568
|
|
enlarged lymph nodes |
J:123568
|
|
enlarged spleen |
J:123568
|
|
increased B cell number |
J:123568
|
|
increased B-1a cell number |
J:123568
|
|
increased granulocyte number |
J:123568
|
|
increased macrophage cell number |
J:123568
|
|
increased plasma cell number |
J:123568
|
|
increased susceptibility to systemic lupus erythematosus |
J:123568
|
|
increased T cell number |
J:123568
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1Uzs/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * BALB/c
|
normal
immune system phenotype |
J:130768
|
Cd19tm1(cre)Cgn/Cd19+
Traf3tm1Rbr/Traf3tm1Rbr
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal B cell physiology |
J:132877
|
|
increased follicular B cell number |
J:132877
|
|
increased marginal zone B cell number |
J:132877
|
|
lymph node hyperplasia |
J:132877
|
Cd19tm1(cre)Cgn/Cd19+
Pbx1tm2Mlc/Pbx1tm2Mlc
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
no abnormal phenotype detected |
J:132963
|
Cd19tm1(cre)Cgn/Cd19+
Tcf3tm1Mbu/Tcf3tm1.2Mbu
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
decreased B cell number |
J:137719
|
|
decreased immature B cell number |
J:137719
|
|
decreased mature B cell number |
J:137719
|
|
decreased pre-B cell number |
J:137719
|
|
decreased pro-B cell number |
J:137719
|
|
decreased transitional stage B cell number |
J:137719
|
Cd19tm1(cre)Cgn/Cd19+
Tcf3tm1Mbu/Tcf3tm1.2Mbu
Tg(Vav-BCL2)69Jad/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL
|
decreased pre-B cell number |
J:137719
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm5(Map3k14)Rsky/Gt(ROSA)26Sortm5(Map3k14)Rsky
involves: 129P2/OlaHsd * C57BL/6
|
enlarged lymph nodes |
J:139293
|
|
enlarged spleen |
J:139293
|
|
increased marginal zone B cell number |
J:139293
|
|
increased mature B cell number |
J:139293
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm5(Map3k14)Rsky/Gt(ROSA)26Sortm5(Map3k14)Rsky
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6
|
decreased lymphocyte cell number |
J:139293
|
|
decreased mature B cell number |
J:139293
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm6(Map3k14*)Rsky/Gt(ROSA)26Sortm6(Map3k14*)Rsky
involves: 129P2/OlaHsd * C57BL/6
|
abnormal Peyer's patch morphology |
J:139293
|
|
abnormal spleen B cell follicle morphology |
J:139293
|
|
decreased B-1 B cell number |
J:139293
|
|
enlarged lymph nodes |
J:139293
|
|
enlarged spleen |
J:139293
|
|
increased mature B cell number |
J:139293
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm6(Map3k14*)Rsky/Gt(ROSA)26Sortm6(Map3k14*)Rsky
Tnfrsf13ctm1Mass/Tnfrsf13ctm1Mass
involves: 129P2/OlaHsd * C57BL/6
|
increased lymphocyte cell number |
J:139293
|
|
increased mature B cell number |
J:139293
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(Cd74/MOG)Awai/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:140751
|
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:140751
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(Cd74/MOG)Awai/Gt(ROSA)26Sor+
Il10tm1Roer/Il10tm1Roer
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:140751
|
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:140751
|
Cd19tm1(cre)Cgn/Cd19+
Kmt2atm1.1Erns/Kmt2atm1.1Erns
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL
|
normal
immune system phenotype |
J:147265
|
Cd19tm1(cre)Cgn/Cd19+
Ep300tm2Reck/Ep300+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
|
abnormal adaptive immunity |
J:147840
|
|
abnormal B cell differentiation |
J:147840
|
|
abnormal humoral immune response |
J:147840
|
|
abnormal renal glomerulus morphology |
J:147840
|
|
abnormal spleen marginal zone macrophage morphology |
J:147840
|
|
abnormal transitional stage B cell morphology |
J:147840
|
|
arteritis |
J:147840
|
|
decreased B cell proliferation |
J:147840
|
|
decreased marginal zone B cell number |
J:147840
|
|
enlarged lymph nodes |
J:147840
|
|
enlarged spleen |
J:147840
|
|
extramedullary hematopoiesis |
J:147840
|
|
glomerulonephritis |
J:147840
|
|
increased activated T cell number |
J:147840
|
|
increased anti-double stranded DNA antibody level |
J:147840
|
|
increased B cell apoptosis |
J:147840
|
|
increased B cell number |
J:147840
|
|
increased IgG2b level |
J:147840
|
|
increased immunoglobulin level |
J:147840
|
|
increased megakaryocyte cell number |
J:147840
|
|
increased spleen weight |
J:147840
|
|
increased susceptibility to systemic lupus erythematosus |
J:147840
|
|
intermingled spleen red and white pulp |
J:147840
|
|
kidney inflammation |
J:147840
|
|
premature death |
J:147840
|
|
renal fibrosis |
J:147840
|
|
renal glomerular protein deposits |
J:147840
|
Cd19tm1(cre)Cgn/Cd19+
Ep300tm2Reck/Ep300+
involves: 129/Sv * 129P2/OlaHsd * FVB/N
|
increased susceptibility to systemic lupus erythematosus |
J:147840
|
|
premature death |
J:147840
|
Cd19tm1(cre)Cgn/Cd19+
Slc3a2tm1.1Mgin/Slc3a2tm1.1Mgin
involves: 129 * C57BL/6 * SJL
|
abnormal B cell activation |
J:148000
|
|
abnormal B cell physiology |
J:148000
|
|
abnormal class switch recombination |
J:148000
|
|
abnormal plasma cell differentiation |
J:148000
|
|
decreased B cell proliferation |
J:148000
|
|
decreased germinal center B cell number |
J:148000
|
|
decreased IgG level |
J:148000
|
|
decreased IgM level |
J:148000
|
|
normal
immune system phenotype |
J:148000
|
Cd19tm1(cre)Cgn/Cd19+
Slc3a2tm1.1Mgin/Slc3a2tm1Yai
involves: 129 * C57BL/6 * SJL
|
decreased IgG3 level |
J:148000
|
|
decreased IgM level |
J:148000
|
Cd19tm1(cre)Cgn/Cd19+
Mirc30tm1.1Rdf/Mirc30tm1.1Rdf
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6
|
increased B cell derived lymphoma incidence |
J:156946
|
|
increased B cell number |
J:156946
|
|
increased B-1a cell number |
J:156946
|
|
increased leukemia incidence |
J:156946
|
|
increased spleen white pulp amount |
J:156946
|
Cd19tm1(cre)Cgn/Cd19+
Il10ratm1.1Jack/Il10ratm1.1Jack
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
normal
immune system phenotype |
J:157787
|
Cd19tm1(cre)Cgn/Cd19+
Ltbrtm1Avt/Ltbrtm1Avt
involves: 129P2/OlaHsd
|
normal
immune system phenotype |
J:158663
|
Cd19tm1(cre)Cgn/Cd19+
Ltbrtm1Avt/Ltbrtm1Avt
Tg(Lck-cre)I57Jxm/0
involves: 129P2/OlaHsd
|
normal
immune system phenotype |
J:158663
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd
|
abnormal T cell activation |
J:160931
|
|
cachexia |
J:160931
|
|
enlarged spleen |
J:160931
|
|
increased T cell derived lymphoma incidence |
J:160931
|
|
increased T cell proliferation |
J:160931
|
|
premature death |
J:160931
|
Cd19tm1(cre)Cgn/Cd19+
Tnfaip3tm2Ama/Tnfaip3+
involves: 129P2/OlaHsd * C57BL/6
|
decreased B cell apoptosis |
J:163917
|
|
increased autoantibody level |
J:163917
|
|
increased germinal center B cell number |
J:163917
|
|
increased immunoglobulin level |
J:163917
|
|
increased plasma cell number |
J:163917
|
|
increased susceptibility to autoimmune disorder |
J:163917
|
Cd19tm1(cre)Cgn/Cd19+
Rapgef2tm1.1Hous/Rapgef2tm1.1Hous
involves: 129P2/OlaHsd * 129S1/Sv
|
normal
hematopoietic system phenotype |
J:165879
|
|
normal
immune system phenotype |
J:165879
|
Cd19tm1(cre)Cgn/Cd19+
Irf8tm1.1Hm/Irf8tm1.1Hm
involves: 129P2/OlaHsd * C57BL/6
|
abnormal spleen marginal zone morphology |
J:168923
|
|
decreased follicular B cell number |
J:168923
|
|
normal
immune system phenotype |
J:168923
|
|
increased B cell number |
J:168923
|
|
increased B-2 B cell number |
J:168923
|
|
increased follicular B cell number |
J:168923
|
|
increased marginal zone B cell number |
J:168923
|
|
increased transitional stage B cell number |
J:168923
|
Cd19tm1(cre)Cgn/Cd19+
Derl2tm1.1Hpl/Derl2tm1.1Hpl
involves: 129P2/OlaHsd
|
normal
immune system phenotype |
J:170650
|
Cd19tm1(cre)Cgn/Cd19+
Cd1d1tm1.1Aben/Cd1d1tm1.1Aben
B6.Cg-Cd1d1tm1.1Aben Cd19tm1(cre)Cgn
|
normal
immune system phenotype |
J:183087
|
Cd19tm1(cre)Cgn/Cd19+
Tnfaip3tm1.1Awai/Tnfaip3tm1.1Awai
involves: 129P2/OlaHsd
|
decreased B-1a cell number |
J:175422
|
|
decreased B-1b cell number |
J:175422
|
|
decreased marginal zone B cell number |
J:175422
|
|
decreased mature B cell number |
J:175422
|
|
enlarged spleen |
J:175422
|
|
increased anti-nuclear antigen antibody level |
J:175422
|
|
increased B cell number |
J:175422
|
|
increased B cell proliferation |
J:175422
|
|
increased follicular B cell number |
J:175422
|
|
increased germinal center B cell number |
J:175422
|
|
increased IgA level |
J:175422
|
|
increased IgG2a level |
J:175422
|
|
increased IgM level |
J:175422
|
|
increased splenocyte number |
J:175422
|
|
increased T cell number |
J:175422
|
Cd19tm1(cre)Cgn/Cd19+
Ptpn11tm1Ckq/Ptpn11+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
|
increased acute lymphoblastic leukemia incidence |
J:177285
|
|
increased B cell derived lymphoma incidence |
J:177285
|
|
premature death |
J:177285
|
Cd19tm1(cre)Cgn/Cd19+
Trp53tm1Yjc/Trp53tm1Yjc
involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6
|
normal
neoplasm |
J:195018
|
Cd19tm1(cre)Cgn/Cd19+
Ell2tm1.1Cmil/Ell2tm1.1Cmil
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
abnormal endoplasmic reticulum morphology |
J:234692
|
|
decreased IgA level |
J:234692
|
|
decreased IgG1 level |
J:234692
|
|
decreased IgM level |
J:234692
|
|
decreased immunoglobulin level |
J:234692
|
|
decreased mature B cell number |
J:234692
|
|
decreased plasma cell number |
J:234692
|
|
decreased transitional stage T1 B cell number |
J:234692
|
|
decreased transitional stage T2 B cell number |
J:234692
|
|
decreased transitional stage T3 B cell number |
J:234692
|
|
impaired humoral immune response |
J:234692
|
|
increased follicular B cell number |
J:234692
|
|
increased immature B cell number |
J:234692
|
|
increased pre-B cell number |
J:234692
|
|
increased pro-B cell number |
J:234692
|
Cd19tm1(cre)Cgn/Cd19+
Ell2tm2.1Cmil/Ell2tm2.1Cmil
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
decreased IgA level |
J:234692
|
|
decreased IgG1 level |
J:234692
|
|
decreased IgM level |
J:234692
|
|
decreased immunoglobulin level |
J:234692
|
|
decreased mature B cell number |
J:234692
|
Cd19tm1(cre)Cgn/Cd19+
Ctnnbl1tm1.1Crad/Ctnnbl1tm1.1Crad
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
decreased B cell proliferation |
J:232010
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd
|
abnormal B cell activation |
J:228288
|
|
abnormal bone marrow cell number |
J:228288
|
|
abnormal plasmablast number |
J:228288
|
|
abnormal spleen morphology |
J:228288
|
|
enlarged lymph nodes |
J:228288
|
|
enlarged spleen |
J:228288
|
|
increased B cell derived lymphoma incidence |
J:228288
|
|
increased B cell number |
J:228288
|
|
increased B cell proliferation |
J:228288
|
|
increased plasma cell number |
J:228288
|
|
postnatal lethality, complete penetrance |
J:228288
|
|
spleen hyperplasia |
J:228288
|
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
Malt1tm1Mak/Malt1tm1Mak
involves: 129P2/OlaHsd
|
normal
immune system phenotype |
J:228288
|
|
normal
mortality/aging |
J:228288
|
Cd19tm1(cre)Cgn/Cd19+
Myd88em1.1Rsky/Myd88+
involves: C57BL/6NTac
|
abnormal splenic cell ratio |
J:308792
|
|
enlarged spleen |
J:308792
|
|
normal
hematopoietic system phenotype |
J:308792
|
|
increased germinal center B cell number |
J:308792
|
|
increased IgM level |
J:308792
|
|
increased plasma cell number |
J:308792
|
Cd19tm1(cre)Cgn/Cd19+
Myd88em1.1Rsky/Myd88em1.1Rsky
involves: C57BL/6NTac
|
increased B cell proliferation |
J:308792
|
Cd19tm1(cre)Cgn/Cd19+
Tbl1xr1tm1c(EUCOMM)Hmgu/Tbl1xr1tm1c(EUCOMM)Hmgu
Tg(Vav-BCL2)69Jad/0
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N
|
abnormal B cell differentiation |
J:292118
|
|
abnormal lymphocyte morphology |
J:292118
|
|
abnormal spleen morphology |
J:292118
|
|
increased organ/body region tumor incidence |
J:292118
|
|
premature death |
J:292118
|
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ightm1Mnz/Ightm1Mnz
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:75653
|
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ightm2Mnz/Ightm2Mnz
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:75653
|
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae
|
normal
immune system phenotype |
J:83213
|
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Tg(IghelMD4)4Ccg/0
involves: 129P2/OlaHsd * C57BL/6
|
decreased B cell number |
J:155314
|
|
normal
immune system phenotype |
J:155314
|
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * C57BL/6
|
decreased B cell number |
J:155314
|
|
normal
immune system phenotype |
J:155314
|
Cd19tm1(cre)Cgn/?
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sortm1(HBEGF)Awai
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell morphology |
J:131076
|
|
abnormal bone marrow cell number |
J:131076
|
|
abnormal lymph node cell ratio |
J:131076
|
|
abnormal lymphocyte cell number |
J:131076
|
|
abnormal lymphocyte morphology |
J:131076
|
|
abnormal splenic cell ratio |
J:131076
|
|
absent immature B cells |
J:131076
|
|
absent mature B cells |
J:131076
|
Cd19tm1(cre/ERT2)Rsky/Cd19+
Myd88em1.1Rsky/Myd88+
involves: 129P2/OlaHsd * C57BL/6NTac
|
increased IgM level |
J:308792
|
|
increased plasma cell number |
J:308792
|
Cd19tm1Tft/Cd19tm1Tft
Lyntm1Sor/Lyntm1Sor
involves: 129S4/SvJaeSor * C57BL/6
|
abnormal humoral immune response |
J:71174
|
|
decreased anti-double stranded DNA antibody level |
J:71174
|
|
decreased B cell number |
J:71174
|
|
decreased B cell proliferation |
J:71174
|
|
decreased B-1 B cell number |
J:71174
|
|
decreased mature B cell number |
J:71174
|
|
decreased susceptibility to systemic lupus erythematosus |
J:71174
|
|
enlarged spleen |
J:71174
|
|
normal
immune system phenotype |
J:71174
|
Cxcr4tm2Yzo/Cxcr4tm2Yzo
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd
|
abnormal B cell differentiation |
J:94911
|
|
abnormal Peyer's patch follicle morphology |
J:94911
|
|
decreased B-1 B cell number |
J:94911
|
|
decreased B-2 B cell number |
J:94911
|
|
decreased immunoglobulin level |
J:94911
|
|
decreased mature B cell number |
J:94911
|
|
decreased plasma cell number |
J:94911
|
Cxcr4tm2Yzo/Cxcr4tm3.1Yzo
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd
|
abnormal B cell differentiation |
J:167314
|
Del(14Trim13-Rnaseh2b)6Rdf/+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6
|
abnormal lymphopoiesis |
J:179879
|
|
increased B cell number |
J:179879
|
|
increased chronic lymphocytic leukemia incidence |
J:179879
|
|
increased lymphoma incidence |
J:179879
|
|
increased small lymphocytic lymphoma incidence |
J:179879
|
|
premature death |
J:179879
|
Dhx15tm1c(EUCOMM)Wtsi/Dhx15tm1c(EUCOMM)Wtsi
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C3H * C57BL/6N
|
abnormal B cell differentiation |
J:284624
|
|
decreased B cell number |
J:284624
|
|
decreased B cell proliferation |
J:284624
|
|
decreased pre-B cell number |
J:284624
|
|
decreased spleen weight |
J:284624
|
|
spleen hypoplasia |
J:284624
|
Ebf1tm1.1Rug/Ebf1tm1.1Rug
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
decreased B-1 B cell number |
J:182210
|
|
decreased marginal zone B cell number |
J:182210
|
Ezh2tm1.1Nesh/Ezh2+
Cd19tm1(cre)Cgn/Cd19+
involves: 129 * 129P2/OlaHsd * C57BL/6
|
abnormal spleen morphology |
J:239472
|
|
abnormal spleen white pulp morphology |
J:239472
|
|
enlarged lymph nodes |
J:239472
|
|
enlarged spleen |
J:239472
|
|
increased B cell derived lymphoma incidence |
J:239472
|
|
increased leukemia incidence |
J:239472
|
|
premature death |
J:239472
|
Ezh2tm1.1Nesh/Ezh2tm1.1Nesh
Cd19tm1(cre)Cgn/Cd19+
involves: 129 * 129P2/OlaHsd * C57BL/6
|
enlarged lymph nodes |
J:239472
|
|
enlarged spleen |
J:239472
|
|
increased B cell derived lymphoma incidence |
J:239472
|
Ezh2tm1Tara/Ezh2tm1Tara
Cd19tm1(cre)Cgn/?
involves: 129P2/OlaHsd
|
normal
immune system phenotype |
J:83216
|
Faslpr/Faslpr
Hspa13tm1.1Smoc/Hspa13tm1.1Smoc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp
|
decreased autoantibody level |
J:303927
|
|
decreased susceptibility to systemic lupus erythematosus |
J:303927
|
|
increased urine protein level |
J:303927
|
Fastm1Cgn/Fastm1Cgn
Cd19tm1(cre)Cgn/Cd19+
Tg(Cd4-cre)1Cwi/0
B6.Cg-Tg(Cd4-cre)1Cwi Cd19tm1(cre)Cgn Fastm1Cgn
|
increased anti-single stranded DNA antibody level |
J:114948
|
Gt(ROSA)26Sortm1(CAG-Bcl3,-EGFP)Hoev/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd
|
abnormal B cell differentiation |
J:208980
|
|
abnormal B-2 B cell morphology |
J:208980
|
|
abnormal class switch recombination |
J:208980
|
|
abnormal follicular B cell morphology |
J:208980
|
|
abnormal Peyer's patch germinal center morphology |
J:208980
|
|
abnormal transitional stage T3 B cell morphology |
J:208980
|
|
absent marginal zone B cells |
J:208980
|
|
decreased B cell apoptosis |
J:208980
|
|
decreased B cell proliferation |
J:208980
|
|
decreased B-1 B cell number |
J:208980
|
|
decreased B-1a cell number |
J:208980
|
|
decreased IgG1 level |
J:208980
|
|
decreased IgG2b level |
J:208980
|
|
decreased IgG3 level |
J:208980
|
|
decreased IgM level |
J:208980
|
|
decreased immature B cell number |
J:208980
|
|
decreased marginal zone B cell number |
J:208980
|
|
decreased transitional stage T1 B cell number |
J:208980
|
|
enlarged spleen |
J:208980
|
|
increased lymphocyte cell number |
J:208980
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Rev3ltm1.1Diaz/Rev3ltm1.1Diaz
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6NTac
|
abnormal class switch recombination |
J:188723
|
|
abnormal somatic hypermutation frequency |
J:188723
|
|
decreased B cell proliferation |
J:188723
|
|
normal
immune system phenotype |
J:188723
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)
|
abnormal class switch recombination |
J:172031
|
|
absent spleen germinal center |
J:172031
|
|
decreased B cell apoptosis |
J:172031
|
|
decreased B cell number |
J:172031
|
|
decreased germinal center B cell number |
J:172031
|
|
decreased IgA level |
J:172031
|
|
decreased IgG1 level |
J:172031
|
|
decreased IgG2a level |
J:172031
|
|
decreased IgG3 level |
J:172031
|
|
decreased plasma cell number |
J:172031
|
|
decreased tumor-free survival time |
J:172031
|
|
enlarged spleen |
J:172031
|
|
increased B cell number |
J:172031
|
|
increased histiocytic sarcoma incidence |
J:172031
|
|
increased IgE level |
J:172031
|
|
increased macrophage cell number |
J:172031
|
|
increased marginal zone B cell number |
J:172031
|
|
increased sarcoma incidence |
J:172031
|
|
increased spleen weight |
J:172031
|
|
increased T cell number |
J:172031
|
|
increased tumor incidence |
J:172031
|
Gt(ROSA)26Sortm1(Ptpn22*)Draw/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
enlarged spleen |
J:201448
|
|
expanded mesangial matrix |
J:201448
|
|
glomerulonephritis |
J:201448
|
|
increased anti-double stranded DNA antibody level |
J:201448
|
|
increased autoantibody level |
J:201448
|
|
increased B cell number |
J:201448
|
|
increased germinal center B cell number |
J:201448
|
|
spleen hyperplasia |
J:201448
|
Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
|
abnormal B cell differentiation |
J:179036
|
|
abnormal marginal zone B cell physiology |
J:179036
|
|
abnormal spleen marginal zone morphology |
J:179036
|
|
decreased B cell number |
J:179036
|
|
decreased B-1a cell number |
J:179036
|
|
decreased B-2 B cell number |
J:179036
|
|
decreased follicular B cell number |
J:179036
|
|
decreased IgG1 level |
J:179036
|
|
decreased IgG3 level |
J:179036
|
|
decreased IgM level |
J:179036
|
|
decreased spleen B cell follicle size |
J:179036
|
|
decreased spleen germinal center number |
J:179036
|
|
decreased transitional stage T2 B cell number |
J:179036
|
|
increased B cell proliferation |
J:179036
|
|
increased marginal zone B cell number |
J:179036
|
|
increased spleen weight |
J:179036
|
|
increased T cell number |
J:179036
|
|
increased transitional stage T1 B cell number |
J:179036
|
Gt(ROSA)26Sortm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
|
abnormal B cell differentiation |
J:179036
|
|
abnormal spleen marginal zone morphology |
J:179036
|
|
decreased follicular B cell number |
J:179036
|
|
decreased mature B cell number |
J:179036
|
|
decreased pre-B cell number |
J:179036
|
|
decreased transitional stage T2 B cell number |
J:179036
|
|
increased marginal zone B cell number |
J:179036
|
|
increased transitional stage T1 B cell number |
J:179036
|
Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
abnormal B cell activation |
J:137122
|
|
abnormal B cell physiology |
J:137122
|
|
abnormal class switch recombination |
J:137122
|
|
abnormal humoral immune response |
J:137122
|
|
abnormal T cell activation |
J:137122
|
|
enlarged inguinal lymph nodes |
J:137122
|
|
enlarged liver |
J:137122
|
|
enlarged spleen |
J:137122
|
|
increased B cell derived lymphoma incidence |
J:137122
|
|
increased B cell number |
J:137122
|
|
increased B cell proliferation |
J:137122
|
|
increased follicular B cell number |
J:137122
|
|
increased marginal zone B cell number |
J:137122
|
|
increased spleen B cell follicle size |
J:137122
|
|
increased spleen weight |
J:137122
|
|
increased T cell number |
J:137122
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ
|
enlarged spleen |
J:181546
|
|
increased B cell number |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ
|
enlarged liver |
J:181546
|
|
enlarged spleen |
J:181546
|
|
increased B cell derived lymphoma incidence |
J:181546
|
|
increased B cell number |
J:181546
|
|
increased plasmacytoma incidence |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/cJ
|
abnormal B cell differentiation |
J:181546
|
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:181546
|
|
abnormal immune system physiology |
J:181546
|
|
decreased B cell number |
J:181546
|
|
decreased mature B cell number |
J:181546
|
|
decreased pre-B cell number |
J:181546
|
|
enlarged spleen |
J:181546
|
|
increased B cell number |
J:181546
|
|
increased B cell proliferation |
J:181546
|
|
increased CD4-positive, alpha-beta T cell number |
J:181546
|
|
increased CD8-positive, alpha-beta T cell number |
J:181546
|
|
increased pro-B cell number |
J:181546
|
|
increased susceptibility to induced morbidity/mortality |
J:181546
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6
|
normal
neoplasm |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
enlarged spleen |
J:181546
|
|
increased B cell number |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
enlarged liver |
J:181546
|
|
enlarged spleen |
J:181546
|
|
increased B cell derived lymphoma incidence |
J:181546
|
|
increased B cell number |
J:181546
|
|
increased plasmacytoma incidence |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell differentiation |
J:181546
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:181546
|
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:181546
|
|
abnormal immune system physiology |
J:181546
|
|
decreased B cell number |
J:181546
|
|
decreased mature B cell number |
J:181546
|
|
decreased pre-B cell number |
J:181546
|
|
enlarged spleen |
J:181546
|
|
increased B cell number |
J:181546
|
|
increased B cell proliferation |
J:181546
|
|
increased CD4-positive, alpha-beta T cell number |
J:181546
|
|
increased CD8-positive, alpha-beta T cell number |
J:181546
|
|
increased interferon-gamma secretion |
J:181546
|
|
increased pro-B cell number |
J:181546
|
|
increased susceptibility to induced morbidity/mortality |
J:181546
|
|
increased tumor necrosis factor secretion |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
normal
neoplasm |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre/ERT2)Rsky/Cd19+
involves: 129P2/OlaHsd * C57BL/6J
|
abnormal T cell physiology |
J:217520
|
|
enlarged spleen |
J:217520
|
|
increased activated T cell number |
J:217520
|
|
increased B cell number |
J:217520
|
|
increased CD4-positive, alpha-beta T cell number |
J:217520
|
|
increased CD8-positive, alpha-beta T cell number |
J:217520
|
H2-Ab1b-tm1Wug/H2-Ab1b-tm1Wug
Cd19tm1(cre)Cgn/Cd19+
involves: 129S2/SvPas * C57BL/6
|
abnormal B cell physiology |
J:204951
|
|
abnormal dendritic cell physiology |
J:204951
|
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:204951
|
|
normal
immune system phenotype |
J:204951
|
Hspa13tm1.1Smoc/Hspa13tm1.1Smoc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S * C57BL/6
|
abnormal class switch recombination |
J:303927
|
|
abnormal humoral immune response |
J:303927
|
|
abnormal plasmablast number |
J:303927
|
|
abnormal somatic hypermutation frequency |
J:303927
|
|
decreased autoantibody level |
J:303927
|
|
decreased IgA level |
J:303927
|
|
decreased IgE level |
J:303927
|
|
decreased IgG1 level |
J:303927
|
|
decreased IgG2b level |
J:303927
|
|
decreased IgG2c level |
J:303927
|
|
decreased IgG3 level |
J:303927
|
|
decreased IgG level |
J:303927
|
|
decreased IgM level |
J:303927
|
|
decreased plasma cell number |
J:303927
|
|
decreased susceptibility to injury |
J:303927
|
|
increased urine protein level |
J:303927
|
Is(14)1Rdf/Is(14)1Rdf
Is(14)5Rdf/Is(14)5Rdf
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6
|
abnormal lymphopoiesis |
J:179879
|
|
increased B cell number |
J:179879
|
|
increased chronic lymphocytic leukemia incidence |
J:179879
|
|
increased lymphoma incidence |
J:179879
|
|
increased small lymphocytic lymphoma incidence |
J:179879
|
|
premature death |
J:179879
|
Is(14)1Rdf Is(14)2Rdf/Del(14Trim13-Dleu2)4Rdf
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6
|
increased B cell derived lymphoma incidence |
J:156946
|
|
increased B cell number |
J:156946
|
|
increased B-1a cell number |
J:156946
|
|
increased leukemia incidence |
J:156946
|
|
increased spleen white pulp amount |
J:156946
|
Is(14)1Rdf Is(14)5Rdf/Del(14Trim13-Rnaseh2b)6Rdf
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6
|
abnormal lymphopoiesis |
J:179879
|
|
increased B cell number |
J:179879
|
|
increased chronic lymphocytic leukemia incidence |
J:179879
|
|
increased lymphoma incidence |
J:179879
|
|
increased small lymphocytic lymphoma incidence |
J:179879
|
|
premature death |
J:179879
|
Itgavtm2Hyn/Itgavtm2.1Hyn
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB
|
normal
digestive/alimentary phenotype |
J:125508
|
Kmt2dtm1.1Kaig/Kmt2d+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
increased germinal center B cell number |
J:228913
|
|
increased spleen germinal center size |
J:228913
|
Kmt2dtm1.1Kaig/Kmt2dtm1.1Kaig
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell differentiation |
J:228913
|
|
decreased B cell number |
J:228913
|
|
decreased follicular B cell number |
J:228913
|
|
decreased IgG1 level |
J:228913
|
|
decreased IgM level |
J:228913
|
|
decreased mature B cell number |
J:228913
|
|
normal
immune system phenotype |
J:228913
|
|
increased B cell proliferation |
J:228913
|
|
increased germinal center B cell number |
J:228913
|
|
increased spleen germinal center number |
J:228913
|
|
increased spleen germinal center size |
J:228913
|
Lmo2tm3Thr/Lmo2tm4Thr
Cd19tm1(cre)Thr/Cd19+
involves: 129S/SvEv
|
normal
hematopoietic system phenotype |
J:86869
|
|
normal
immune system phenotype |
J:86869
|
Map3k14tm1.1Gne/Map3k14tm1.1Gne
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac
|
decreased B cell number |
J:280549
|
Map3k14tm1.1Gne/Map3k14tm1.1Gne
Otub1tm1c(EUCOMM)Hmgu/Otub1tm1c(EUCOMM)Hmgu
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * C57BL/6NTac
|
normal
immune system phenotype |
J:280549
|
Mcm3aptm1Imku/Mcm3aptm1Imku
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
abnormal germinal center B cell physiology |
J:88276
|
|
abnormal memory B cell number |
J:88276
|
|
abnormal spleen germinal center morphology |
J:88276
|
|
decreased B cell number |
J:88276
|
|
decreased B cell proliferation |
J:88276
|
|
decreased germinal center B cell number |
J:88276
|
|
decreased IgG level |
J:88276
|
Mir148atm2942.1Arte/Mir148atm2942.1Arte
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal plasmablast number |
J:307366
|
|
decreased IgA level |
J:307366
|
|
decreased IgG level |
J:307366
|
|
decreased IgM level |
J:307366
|
|
decreased plasma cell number |
J:307366
|
|
impaired humoral immune response |
J:307366
|
|
increased memory B cell number |
J:307366
|
Myctm2Fwa/Myctm2Fwa
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
decreased B cell proliferation |
J:67222
|
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
normal
immune system phenotype |
J:195140
|
Nabp2tm1.1Nfel/Nabp2tm1.2Nfel
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL
|
normal
immune system phenotype |
J:190019
|
Nfkb2Lym1/Nfkb2+
Otub1tm1c(EUCOMM)Hmgu/Otub1tm1c(EUCOMM)Hmgu
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * BALB/c * C57BL/6 * C57BL/6N
|
normal
immune system phenotype |
J:280549
|
Nle1tm1Cba/Nle1tm1.1Cota
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas
|
normal
hematopoietic system phenotype |
J:204063
|
|
normal
immune system phenotype |
J:204063
|
Otub1tm1c(EUCOMM)Hmgu/Otub1tm1c(EUCOMM)Hmgu
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N
|
abnormal B cell activation |
J:280549
|
|
abnormal follicular B cell morphology |
J:280549
|
|
decreased B-1 B cell number |
J:280549
|
|
decreased immature B cell number |
J:280549
|
|
decreased T cell number |
J:280549
|
|
enlarged spleen |
J:280549
|
|
increased anti-double stranded DNA antibody level |
J:280549
|
|
increased anti-nuclear antigen antibody level |
J:280549
|
|
increased B cell number |
J:280549
|
|
increased B-2 B cell number |
J:280549
|
|
increased circulating interleukin-6 level |
J:280549
|
|
increased IgA level |
J:280549
|
|
increased IgG2a level |
J:280549
|
|
increased IgG2b level |
J:280549
|
|
increased IgM level |
J:280549
|
|
increased immunoglobulin level |
J:280549
|
|
increased marginal zone B cell number |
J:280549
|
|
increased mature B cell number |
J:280549
|
|
increased susceptibility to autoimmune disorder |
J:280549
|
|
increased susceptibility to systemic lupus erythematosus |
J:280549
|
Palb2tm1.1Dli/Palb2tm1.1Dli
Trp53bp1tm1Jc/Trp53bp1tm1Jc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6
|
chromosome breakage |
J:197442
|
Pax5tm3Mbu/Pax5+
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal pro-B cell morphology |
J:226241
|
|
arrested B cell differentiation |
J:226241
|
|
decreased immature B cell number |
J:226241
|
|
increased B cell acute lymphoblastic leukemia incidence |
J:226241
|
Pcid2tm1Imku/Pcid2tm1Imku
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
abnormal spleen B cell follicle morphology |
J:166080
|
|
decreased follicular B cell number |
J:166080
|
|
decreased marginal zone B cell number |
J:166080
|
|
decreased mature B cell number |
J:166080
|
Pdap1em1Rkuhn/Pdap1em1Rkuhn
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N
|
abnormal B cell physiology |
J:298705
|
|
abnormal class switch recombination |
J:298705
|
|
abnormal mitochondrial physiology |
J:298705
|
|
abnormal somatic hypermutation frequency |
J:298705
|
|
decreased germinal center B cell number |
J:298705
|
|
decreased mature B cell number |
J:298705
|
|
increased B cell apoptosis |
J:298705
|
Pgap3tm1Ymra/Pgap3tm1Ymra
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd
|
normal
immune system phenotype |
J:203443
|
Pik3cdtm1Tnr/Pik3cdtm1Tnr
Ptentm2.1Ppp/Ptentm2.1Ppp
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6
|
abnormal class switch recombination |
J:130950
|
|
normal
immune system phenotype |
J:130950
|
|
increased marginal zone B cell number |
J:130950
|
Pik3cdtm2.1Tnr/Pik3cdtm2.1Tnr
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
normal
immune system phenotype |
J:164283
|
|
increased IgE level |
J:164283
|
Prelid1tm1Hmva/Prelid1tm1Hmva
Cd19tm1(cre)Cgn/Cd19+
involves: 129 * 129P2/OlaHsd * C57BL/6
|
no abnormal phenotype detected |
J:187294
|
Ptpmt1tm2.1Ckq/Ptpmt1tm2.1Ckq
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL
|
normal
hematopoietic system phenotype |
J:194929
|
|
normal
immune system phenotype |
J:194929
|
Rbbp8tm1Whl/Rbbp8tm1.1Thl
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S4/SvJaeSor
|
normal
immune system phenotype |
J:194603
|
Rc3h1tm1.1Mass/Rc3h1tm1.1Mass
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * NZB * SJL
|
abnormal effector T cell morphology |
J:177784
|
|
enlarged spleen |
J:177784
|
|
increased B cell number |
J:177784
|
|
increased eosinophil cell number |
J:177784
|
|
increased regulatory T cell number |
J:177784
|
|
increased spleen weight |
J:177784
|
Rnaseh2btm1c(EUCOMM)Wtsi/Rnaseh2btm1c(EUCOMM)Wtsi
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N * SJL
|
decreased B cell proliferation |
J:186986
|
|
normal
immune system phenotype |
J:186986
|
Sh2d1atm2Vei/Sh2d1atm2Vei
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
normal
immune system phenotype |
J:131618
|
Srftm2Nor/Srftm2Nor
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd
|
abnormal mature B cell morphology |
J:124767
|
|
absent marginal zone B cells |
J:124767
|
|
decreased B cell number |
J:124767
|
|
decreased B-1 B cell number |
J:124767
|
Tab2tm2.1Aki/Tab2tm2.1Aki
Tab3tm1Aki/Tab3tm1Aki
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:195289
|
|
abnormal immune serum protein physiology |
J:195289
|
|
decreased B cell proliferation |
J:195289
|
|
decreased B-1a cell number |
J:195289
|
|
decreased circulating interleukin-6 level |
J:195289
|
|
decreased IgD level |
J:195289
|
|
decreased IgE level |
J:195289
|
|
decreased IgG level |
J:195289
|
|
decreased immunoglobulin level |
J:195289
|
|
decreased mature B cell number |
J:195289
|
|
decreased plasma cell number |
J:195289
|
|
increased B cell apoptosis |
J:195289
|
Tbk1tm1Arte/Tbk1tm1Arte
Cd19tm1(cre)Cgn/Cd19+
involves: 129/SvEv * 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:188560
|
|
abnormal class switch recombination |
J:188560
|
|
abnormal kidney physiology |
J:188560
|
|
increased anti-double stranded DNA antibody level |
J:188560
|
|
increased anti-nuclear antigen antibody level |
J:188560
|
|
increased blood urea nitrogen level |
J:188560
|
|
increased circulating creatinine level |
J:188560
|
|
increased IgA level |
J:188560
|
|
increased IgM level |
J:188560
|
|
increased mature B cell number |
J:188560
|
|
increased urine protein level |
J:188560
|
Tbk1tm1Arte/Tbk1tm1Arte
Map3k14tm1Rds/Map3k14tm1Rds
Cd19tm1(cre)Cgn/Cd19+
involves: 129/SvEv * 129P2/OlaHsd * C57BL/6
|
abnormal B cell differentiation |
J:188560
|
|
abnormal immunoglobulin level |
J:188560
|
Tcf3tm1(PBX1)Mlc/Tcf3+
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:226241
|
|
abnormal pro-B cell differentiation |
J:226241
|
|
abnormal pro-B cell morphology |
J:226241
|
|
anemia |
J:226241
|
|
arrested B cell differentiation |
J:226241
|
|
decreased B cell number |
J:226241
|
|
decreased immature B cell number |
J:226241
|
|
enlarged liver |
J:226241
|
|
enlarged lymph nodes |
J:226241
|
|
enlarged spleen |
J:226241
|
|
increased B cell acute lymphoblastic leukemia incidence |
J:226241
|
|
increased leukocyte cell number |
J:226241
|
|
thrombocytopenia |
J:226241
|
Tnftm1.1Sned/Tnftm1.1Sned
Cd19tm1(cre)Cgn/Cd19+
involves: 129 * 129P2/OlaHsd * C57BL/6
|
normal
immune system phenotype |
J:95684
|
Tnfaip3tm2Ama/Tnfaip3tm2Ama
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell activation |
J:163917
|
|
abnormal B cell morphology |
J:163917
|
|
abnormal B-1a B cell morphology |
J:163917
|
|
decreased B cell apoptosis |
J:163917
|
|
decreased B cell number |
J:163917
|
|
increased autoantibody level |
J:163917
|
|
increased B cell number |
J:163917
|
|
increased B cell proliferation |
J:163917
|
|
increased germinal center B cell number |
J:163917
|
|
increased IgG level |
J:163917
|
|
increased IgM level |
J:163917
|
|
increased immature B cell number |
J:163917
|
|
increased immunoglobulin level |
J:163917
|
|
increased interleukin-6 secretion |
J:163917
|
|
increased plasma cell number |
J:163917
|
|
increased susceptibility to autoimmune disorder |
J:163917
|
|
increased T cell number |
J:163917
|
Traf3tm1Bshp/Traf3tm1Bshp
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal adaptive immunity |
J:124329
|
|
abnormal immune system organ morphology |
J:124329
|
|
abnormal immune system physiology |
J:124329
|
|
abnormal kidney morphology |
J:124329
|
|
abnormal leukocyte morphology |
J:124329
|
|
abnormal liver morphology |
J:124329
|
|
abnormal lymph node B cell domain morphology |
J:124329
|
|
abnormal spleen germinal center morphology |
J:124329
|
|
autoimmune response |
J:124329
|
|
decreased B cell apoptosis |
J:124329
|
|
decreased physiological sensitivity to xenobiotic |
J:124329
|
|
decreased T cell number |
J:124329
|
|
enlarged lymph nodes |
J:124329
|
|
enlarged spleen |
J:124329
|
|
increased anti-double stranded DNA antibody level |
J:124329
|
|
increased B cell number |
J:124329
|
|
increased follicular B cell number |
J:124329
|
|
increased IgA level |
J:124329
|
|
increased IgG2a level |
J:124329
|
|
increased IgG2b level |
J:124329
|
|
increased IgG3 level |
J:124329
|
|
increased IgG level |
J:124329
|
|
increased IgM level |
J:124329
|
|
increased marginal zone B cell number |
J:124329
|
|
increased spleen white pulp amount |
J:124329
|
|
increased transitional stage B cell number |
J:124329
|
Zc3h12ctm2c(EUCOMM)Hmgu/Zc3h12ctm2c(EUCOMM)Hmgu
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N
|
normal
immune system phenotype |
J:277714
|
Excel File
Analysis Tools